<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00495586</url>
  </required_header>
  <id_info>
    <org_study_id>P06/31</org_study_id>
    <nct_id>NCT00495586</nct_id>
  </id_info>
  <brief_title>Effectiveness of Antibiotic Therapy for Exacerbations of Chronic Obstructive Pulmonary Disease</brief_title>
  <acronym>TRANCE</acronym>
  <official_title>Situations That do Not Require Antibiotics for Acute Exacerbations of Mild-to-moderate Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalan Society of Family Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondo de Investigacion Sanitaria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Catalan Society of Family Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of antibiotic therapy for
      patients with acute exacerbations of mild-to-moderate chronic obstructive pulmonary disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antibiotics are usually prescribed for acute exacerbations of chronic obstructive pulmonary
      disease (COPD) even though their benefit in mild-to-moderate COPD is not demonstrated. The
      aim of this study is to assess the effectiveness of antibiotic therapy for exacerbations of
      COPD, what clinical variables are associated with an improved clinical response with
      antibiotic therapy with respect to placebo and to identify which patients might recover from
      an acute exacerbation without antibiotic therapy. Methodology: prospective, randomised,
      double blind, placebo-controlled clinical trial, in which exacerbations (at least one
      criterion present: increase of dyspnoea, increase of sputum production and/or increase of
      purulence) of patients older than 40 yr., smokers or ex-smokers of more than 10 pack-years,
      with COPD and FEV1 greater than 50%, diagnosed by spirometry and a predicted ratio
      FEV1/FVC&lt;0.7%. Exclusion criteria: severe COPD (FEV1&lt;50%), active neoplasm, tracheotomy,
      pneumonia, hospitalization criteria, patients previously being on antibiotics,
      immunodepressed, history of hypersensitivity to beta-lactams or intolerance to clavulanate,
      enrollment in other clinical trials, patients who refuse to take part in this study, and
      patients who have not had a spirometry test for the past two years. Sample size: 677
      patients. Interventions: first visit: the patient will be given details of the clinical trial
      and will be asked to sign informed consent; other data: sputum color, chest X-ray ordered to
      rule out pneumonia, C-reactive protein levels, and peak flow measurement. The patient will be
      randomised to receive amoxicillin plus clavulanate or placebo and will be scheduled to return
      for a 2nd follow-up visit after 3 or 4 days to assess the clinical response and peak flow
      measurements and to rule out any worsening of the condition. Third visit: scheduled after
      9-11 days to assess the clinical response, drug-compliance and peak flow measurement. Fourth
      visit after 15-20 days for clinical assessment and to observe whether any relapses have
      occurred. Date of the following exacerbation will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Who Were Cured</measure>
    <time_frame>Day 9-11</time_frame>
    <description>Cure defined as the disappearance of the acute signs and symptoms related to the infection, with complete return to the previous situation of stability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Days Till the Next Exacerbation</measure>
    <time_frame>One year</time_frame>
    <description>For the assessment of the time till next exacerbation patients were monitored over a period of 365 days on a three-monthly basis. Patients were instructed to contact their physician immediately if there was any change in their health status. Diagnosis of a new exacerbation was based on the same clinical criteria described previously. For the calculation of time to the next exacerbation, all clinical failures occurring during therapy were counted as zero exacerbation-free interval days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">318</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pills t.i.d. for 8 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amoxycillin and clavulanic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amoxycillin and clavulanate t.i.d. for 8 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One pill to be taken every eight hours for 8 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>It's placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin and clavulanic acid</intervention_name>
    <description>500-125 mg to be taken every eight hours for 8 days</description>
    <arm_group_label>Amoxycillin and clavulanic acid</arm_group_label>
    <other_name>Augmentine 500-125 mg 24 pills</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute exacerbations (at least one criterion present: increase of dyspnoea, increase of
             sputum production and/or increase of purulence) of

          -  patients older than 40 years old,

          -  smokers or ex-smokers of more than 10 pack-years,

          -  with COPD and FEV1 greater than 50%, diagnosed by spirometry and a predicted ratio
             FEV1/FVC&lt;0.7%.

        Exclusion Criteria:

          -  Severe COPD (FEV1&lt;50%)

          -  Pneumonia

          -  Active neoplasm

          -  Tracheotomy

          -  Criteria for hospitalisation

          -  Patients previously being on antibiotics

          -  Immunodepressed patients

          -  History of hypersensitivity to beta-lactams or intolerance to clavulanate

          -  Enrollment in other clinical trials

          -  Patients who refuse to take part in this study

          -  Patients who have not had a spirometry test for the past two years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl Llor, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catalan Society of Family Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Miravitlles, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Moragas, Family doc.</last_name>
    <role>Study Director</role>
    <affiliation>Catalan Society of Family Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínic</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Healthcare Center La Marina</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08038</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Healthcare Center Figueres</name>
      <address>
        <city>Figueres</city>
        <state>Catalonia</state>
        <zip>17600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Healthcare Center Montilivi</name>
      <address>
        <city>Girona</city>
        <state>Catalonia</state>
        <zip>17003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Healthcare Center Girona-4</name>
      <address>
        <city>Girona</city>
        <state>Catalonia</state>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Healthcare Centre Breda-Hostalric</name>
      <address>
        <city>Hostalric</city>
        <state>Catalonia</state>
        <zip>17450</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Healthcare Center Lleida</name>
      <address>
        <city>Lleida</city>
        <state>Catalonia</state>
        <zip>25001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Healthcare Centre Molins de Rei</name>
      <address>
        <city>Molins de Rey</city>
        <state>Catalonia</state>
        <zip>08750</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Healthcare Centre Olot</name>
      <address>
        <city>Olot</city>
        <state>Catalonia</state>
        <zip>17800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Healthcare Center Reus-3</name>
      <address>
        <city>Reus</city>
        <state>Catalonia</state>
        <zip>43203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Healthcare Center Les Muralles</name>
      <address>
        <city>Tarragona</city>
        <state>Catalonia</state>
        <zip>43003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Healthcare Centre Jaume I</name>
      <address>
        <city>Tarragona</city>
        <state>Catalonia</state>
        <zip>43005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Healthcare Center Valls Urbà</name>
      <address>
        <city>Valls</city>
        <state>Catalonia</state>
        <zip>43600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2007</study_first_submitted>
  <study_first_submitted_qc>July 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2007</study_first_posted>
  <results_first_submitted>January 8, 2012</results_first_submitted>
  <results_first_submitted_qc>March 11, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 13, 2012</results_first_posted>
  <last_update_submitted>March 11, 2012</last_update_submitted>
  <last_update_submitted_qc>March 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catalan Society of Family Medicine</investigator_affiliation>
    <investigator_full_name>Carl Llor</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>353 patients invited to participate in this trial, 32 did not fulfill the inclusion criteria (14 presented a forced expiratory volume in one second [FEV1]/forced vital capacity [FVC] ratio &gt; 70% and 18 a FEV1&lt;50%). Three more had a positive X-ray for pneumonia and were therefore excluded.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo pills t.i.d. for 8 days</description>
        </group>
        <group group_id="P2">
          <title>Amoxycillin and Clavulanic Acid</title>
          <description>Amoxycillin and clavulanate t.i.d. for 8 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo pills t.i.d. for 8 days</description>
        </group>
        <group group_id="B2">
          <title>Amoxycillin and Clavulanic Acid</title>
          <description>Amoxycillin and clavulanate t.i.d. for 8 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="156"/>
            <count group_id="B2" value="162"/>
            <count group_id="B3" value="318"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.8" spread="11.0"/>
                    <measurement group_id="B2" value="68.4" spread="9.9"/>
                    <measurement group_id="B3" value="68.1" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Were Cured</title>
        <description>Cure defined as the disappearance of the acute signs and symptoms related to the infection, with complete return to the previous situation of stability</description>
        <time_frame>Day 9-11</time_frame>
        <population>Clinical cure at end of therapy visit at day 9-11 in the ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo pills t.i.d. for 8 days</description>
          </group>
          <group group_id="O2">
            <title>Amoxycillin and Clavulanic Acid</title>
            <description>Amoxycillin and clavulanate t.i.d. for 8 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Were Cured</title>
          <description>Cure defined as the disappearance of the acute signs and symptoms related to the infection, with complete return to the previous situation of stability</description>
          <population>Clinical cure at end of therapy visit at day 9-11 in the ITT population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the comparison of the efficacy of antibiotic versus placebo, we accepted a null hypothesis if the cure rate in the intervention group was the same or ±7% as that observed in the placebo arm. Based on previous studies, the expected rate of cure among patients assigned to antibiotic therapy was 90%. For an alpha of 0.05 and a beta of 0.2 and accepting possible losses of 15%, we calculated that the sample size is 677 patients in total.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Chi-squared</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>14.2</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>9.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.7</ci_lower_limit>
            <ci_upper_limit>24.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days Till the Next Exacerbation</title>
        <description>For the assessment of the time till next exacerbation patients were monitored over a period of 365 days on a three-monthly basis. Patients were instructed to contact their physician immediately if there was any change in their health status. Diagnosis of a new exacerbation was based on the same clinical criteria described previously. For the calculation of time to the next exacerbation, all clinical failures occurring during therapy were counted as zero exacerbation-free interval days.</description>
        <time_frame>One year</time_frame>
        <population>Patients with clinical success at the end of therapy visit</population>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin and Clavulanic Acid</title>
            <description>Eighty-three exacerbations were reported during the year of follow up among those patients who had clinical success at end of therapy visit (83/143: 58%)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Ninety exacerbations were reported during the year of follow up among those patients who had clinical success at end of therapy visit (90/123: 73.2%)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Till the Next Exacerbation</title>
          <description>For the assessment of the time till next exacerbation patients were monitored over a period of 365 days on a three-monthly basis. Patients were instructed to contact their physician immediately if there was any change in their health status. Diagnosis of a new exacerbation was based on the same clinical criteria described previously. For the calculation of time to the next exacerbation, all clinical failures occurring during therapy were counted as zero exacerbation-free interval days.</description>
          <population>Patients with clinical success at the end of therapy visit</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233" lower_limit="110" upper_limit="365"/>
                    <measurement group_id="O2" value="160" lower_limit="66" upper_limit="365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>20 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo pills t.i.d. for 8 days</description>
        </group>
        <group group_id="E2">
          <title>Amoxycillin and Clavulanic Acid</title>
          <description>Amoxycillin and clavulanate t.i.d. for 8 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disturbance</sub_title>
                <description>32 cases</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The required sample size could not be achieved. This clinical trial was only partially funded by an independent academic institution without any other source of funding. However, due differences obtained the sample size allowed for a power of 80%.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Carl Llor</name_or_title>
      <organization>CAMFIC</organization>
      <phone>+34 3011777</phone>
      <email>carles.llor@urv.cat</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

